Dr. Robert Alter, MD
Claim this profileHackensack University Medical Center
Studies Cancer
Studies Bladder Cancer
15 reported clinical trials
45 drugs studied
Area of expertise
1Cancer
Stage IV
2Bladder Cancer
Stage IV
Stage III
HBcAb negative
Affiliated Hospitals
Clinical Trials Robert Alter, MD is currently running
Standard Therapy + Surgery/Radiation
for Prostate Cancer
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Recruiting2 awards Phase 330 criteria
Cabozantinib +/− Atezolizumab
for Advanced Kidney Cancer
This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and waste as urine. Most papillary tumors look like long, thin finger-like growths under a microscope. It is also called papillary kidney cancer or PRCC. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of cancer cells. Combination therapy with atezolizumab and cabozantinib may shrink the cancer and allow a longer survival time in patients with metastatic renal cell carcinoma.
Recruiting1 award Phase 230 criteria
More about Robert Alter, MD
Clinical Trial Related5 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Robert Alter, MD has experience with
- Nivolumab
- Atezolizumab
- Ipilimumab
- Prednisone
- Radiation Therapy
- Cabozantinib
Breakdown of trials Robert Alter, MD has run
Cancer
Bladder Cancer
Prostate Cancer
Renal Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Robert Alter, MD specialize in?
Robert Alter, MD focuses on Cancer and Bladder Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is Robert Alter, MD currently recruiting for clinical trials?
Yes, Robert Alter, MD is currently recruiting for 9 clinical trials in Hackensack New Jersey. If you're interested in participating, you should apply.
Are there any treatments that Robert Alter, MD has studied deeply?
Yes, Robert Alter, MD has studied treatments such as Nivolumab, Atezolizumab, Ipilimumab.
What is the best way to schedule an appointment with Robert Alter, MD?
Apply for one of the trials that Robert Alter, MD is conducting.
What is the office address of Robert Alter, MD?
The office of Robert Alter, MD is located at: Hackensack University Medical Center, Hackensack, New Jersey 07601 United States. This is the address for their practice at the Hackensack University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.